

CURRICULUM VITAE

Kimberly C. Claeys, PharmD

Associate Professor Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
20 N Pine Street, Baltimore, MD 21201

Office: N432
Phone: 410.706.3215
Fax: 410.706.6580
Email: kclaeys@rx.umaryland.edu

Professional Appointments

- Associate Professor – Infectious Diseases* 07/2021 – present
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, MD
- Research Fellow* 05/2021 – present
Center for Innovation in Diagnosis
University of Maryland School of Medicine
Baltimore, MD
- Assistant Professor – Infectious Diseases* 03/2016 – 07/2021
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, MD
- Infectious Diseases Clinical Pharmacy Specialist* 07/2016 – present
Antimicrobial Stewardship Improving Clinical Outcomes Team
University of Maryland Medical Center
Baltimore, MD

Education & Professional Training

- Doctor of Philosophy Candidate – Epidemiology* 09/2017 – present
Department of Epidemiology and Public Health
University of Maryland School of Medicine,
Baltimore, MD
Advisor: Daniel J. Morgan, MD, MS
- Graduate Certificate in Public Health* 07/2013 – 05/2015
Department of Family Medicine and Public Health Sciences
Wayne State University School of Medicine,
Detroit, MI
- Post-Doctoral Infectious Diseases Health Outcomes Fellowship* 07/2013 – 02/2016
Anti-Infective Research Laboratory
Eugene Applebaum College of Pharmacy and Health Sciences, Wayne
State University,
Detroit, MI
Program Director: Michael J. Rybak, PharmD, MP, PhD

<p><i>ASHP- Accredited PGY1 Pharmacy Residency</i> Department of Pharmacy Practice University of Illinois at Chicago College of Pharmacy, Chicago, IL Program Director: Frank P. Paloucek, PharmD, DABAT</p>	07/2012 – 07/2013
<p><i>Doctor of Pharmacy</i> Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University, Detroit, MI</p>	09/2008 – 05/2012

Licensure & Certifications

<p><i>Maryland Department of Health and Mental Hygiene</i> Registered Pharmacist License No. 24048</p>	04/2016 – present
<p><i>Illinois Department of Financial and Professional Regulation</i> Registered Pharmacist License No. 051296192</p>	09/2012 – present
<p><i>Society of Infectious Diseases Pharmacy</i> Antimicrobial Stewardship Certificate Program</p>	09/2015 – 05/2016
<p><i>Board of Pharmacy Specialties</i> Board Certified Pharmacotherapy Specialist</p>	12/2013 – 12/2020
<p><i>American Heart Association</i> Basic Cardiac Life Support Certification</p>	02/2021 – 02/2023
<p><i>American Pharmacists Association (APhA)</i> Pharmacy-Based Immunization Delivery</p>	09/2008

Institutional Service

<p><i>University of Maryland Medical System</i> Rapid Molecular Diagnostic Testing in Sepsis Working Group</p>	2019 – present
<p><i>University of Maryland Medical Center</i> Antimicrobial Stewardship Subcommittee UMMC Antibiotic Guidebook Editor</p>	2016 – present 2016 – present
<p><i>University of Maryland School of Pharmacy</i> Experiential Learning Committee – Chair Experiential Learning Committee – Chair Elect Research and Entrepreneurship Executive Committee Pharmacometrics Faculty Search Committee Department Strategic Planning Research Committee Residency Research Committee Pharmacotherapy Pathway Committee – Doctor of Pharmacy Program</p>	08/2021 – present 08/2019 – 08/2021 08/2016 – 08/2018 2018 07/2016 – present 04/2016 – 06/2017 04/2016 – present

Professional Service

<i>Antibiotics Journal</i> Editor - Key Collaborations between Antimicrobial Stewardship & Clinical Microbiology – Focus on Diagnostic Stewardship	05/2021 – present
<i>Current Infectious Disease Reports</i> Section Editor - Antimicrobial Development and Drug Resistance	08/2018 – present
<i>Board of Pharmacy Specialties</i> 2021 PSAP Infectious Disease Book Expert Reviewer BCPS Exam Passing Point Committee Member	02/2020 – 07/2020 07/2016
<i>IDWeek Conference</i> Abstract Reviewer - Antimicrobial Agents Including Antibacterial, Antiviral and Antifungal Drugs Abstract Reviewer - Antimicrobial Stewardship, including quality of care	06/2021 – 08/2021 06/2020 – 08/2020
<i>Society of Infectious Diseases Pharmacy</i> Research Committee Publications Committee	09/2016 – present
<i>Society for Healthcare Epidemiology of America (SHEA)</i> Research Committee Member	04/2018 – 12/2020
<i>Nabriva Therapeutics</i> Advisory Board Member	05/2018
<i>Duke Margolis Center for Health Policy</i> Rapid Diagnostic Testing Advisory Board Member	04/2017
<i>Melinta Therapeutics</i> Baxdela Speaker Content Advisory Board	04/2017
<i>Infectious Diseases and Therapy</i> Advisory Board Member	04/2015 – present

Referee for Professional/Scientific Journals

<i>Expert Review of Anti-Infective Therapy</i>	2021 – present
<i>International Journal of Antimicrobial Agents</i>	2021 – present
<i>Clinical Infectious Diseases</i>	2020 – present
<i>British Journal of Clinical Pharmacology</i>	2019
<i>PLOS ONE</i>	2018 – present
<i>Journal of the American College of Clinical Pharmacy</i>	2018 – present
<i>Open Forum Infectious Diseases</i>	2018 – present
<i>BMC Infectious Diseases</i>	2017 – present
<i>Journal of Clinical Microbiology</i>	2017 – present

<i>Antimicrobial Agents and Chemotherapy</i>	2017 – present
<i>Diagnostic Microbiology and Infectious Diseases</i>	2017 – present
<i>Pharmacotherapy</i>	2016 – present
<i>Infectious Diseases and Therapy</i>	2015 – present

Teaching & Precepting

University of Maryland Medical Center *Coordination and Precepting*

Program Co-Coordinator Clinical Microbiology Fellowship	2019 – present
Antimicrobial Stewardship Rotation Pharmacy Practice PGY1 Residency	2018 – present

University of Maryland School of Pharmacy *Coordination and Precepting*

Research Project Coordinator Infectious Diseases PGY2 Residency	2018 – present
Antimicrobial Stewardship Rotation Infectious Diseases PGY2 Residency	2017 – present
Infectious Diseases Consult Rotation Infectious Diseases PGY2 Residency	2017 – present
Infectious Diseases Research Rotation Infectious Diseases PGY2 Residency	2017 – present
APPC Elective - Infectious Diseases & Antimicrobial Stewardship PharmD Students	2017 – present

University of Maryland School of Pharmacy *Lectures and Presentations*

Professional Development Seminar Series – Research Residency and Fellowship Programs	08/2019 – 08/2021
Biostatistics for the Clinical Researcher Preceptor Development Series	11/2018 – present
Resident Seminar Series: Biostatistics Refresher Residency and Fellowship Programs	07/2018 – present
Orientation Session – Biostatistics for Clinical Research Residency and Fellowship Programs	07/2018 – present

Orientation Session – PK/PD of Antimicrobials 07/2017 – present
Pharmacy Practice PGY1 Residency

University of Maryland School of Medicine

Lectures and Presentations

Host Defenses and Infectious Diseases 09/2017 – 09/2019
Antibiotic Development Workshop

University of Maryland School of Medicine

Precepting

Antimicrobial Stewardship Rotation 11/2016 – present
Infectious Diseases Fellows

University of Maryland School of Pharmacy

Course Management

PHMY513 Case-Based Infectious Diseases 2018 – present

PHAR525 Immunology 2018 – present

APPC 476 Advanced Practice Patient Care Elective – ID 2018 – present

University of Maryland School of Pharmacy

Lectures

PHAR5018 Professional Life After Graduation 2017 – present
NAPLEX Review: Infectious Diseases Background

PHMY513 Case-Based Infectious Diseases 2017 – present
Antibiotic Review
Introduction of Case-Based ID/ HAP and VAP
Rapid Diagnostic Testing/Diagnostic Stewardship
MDR Gram-positives

PHAR569 Pharmacotherapy I 2016 – present
Urinary Tract Infections in Older Adults

PHAR570 Pharmacotherapy II 2016 – 2019
Urinary Tract Infections in Immune Compromised Patients

PHAR5017 Infectious Diseases Therapeutics II 2016 – present
Introduction to Bugs and Drugs Part
Understanding and Interpreting Breakpoints, Utilizing Antibiograms
Urinary Tract Infections
Bone and Joint Infections
Central Nervous System Infections
MRSA & VRE
PK/PD lecture
Antibiotic Stewardship

PHAR5016 Infectious Diseases Therapeutics I
Introduction to Bugs and Drugs Part I
Approach to a Patient Case 2016 – present

PHMY539 Special Projects
Project Facilitator - Student Capstone 2016 – present

Eugene Applebaum College of Pharmacy and Health Sciences
Lectures and Facilitator

PHA5175 Pharmacotherapeutic Problem Solving 2014 –2016

PPR5990 Directed Study in Pharmacy Practice 2014 - 2015

PHA4210 Pharmacotherapy Module: Infectious Diseases 2013 –2015

University of Illinois at Chicago College of Pharmacy
Lectures and Facilitator

PHAR 357 Experiential V (Infectious Diseases) 06/2013

Pharmacy Grand Rounds 04/2013

PMPR 385 Case-Based Infectious Diseases 02/2013

Publications

Manuscripts in Peer-Reviewed Journals

1. **Claeys KC**, Schlaffer K, Smith R, Hitchcock S, Jiang Y, Evans SE, Johnson JK, Leekha S.
Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels to Verigene Blood Culture in Gram-negative Bloodstream Infections using DOOR-MAT Analysis. *Clin Infect Dis*. 2021 Mar 27; ciab262. Online ahead of print.
2. **Sullivan KV**, Gallagher JC, Leekha S, Morgan DJ, Morita K, Rock C, **Claeys KC**.
Use of Diagnostic and Antimicrobial Stewardship Practices to Improve *Clostridioides difficile* Testing Among SHEA Research Network Hospitals. *Infect Control Hosp Epidemiol*.
3. Blackman AL, Ali S, Gao X, Mesumbe R, Cheung C, Banoub M, **Claeys KC**, **Heil EL**.
Evaluation of Intra-Operative Topical Vancomycin and the Incidence of Acute Kidney Injury. *Surg Infect (Larchmt)*. 2021 Feb 10. Online ahead of print. PMID: 33571051
4. **Mody L**, Akinboyo IC, Babcock HM, Bischoff WE, Cheng VC, Chiotos K, **Claeys KC**, Coffey KC, Diekema DJ, Donskey CJ, Ellingson KD, Gilmartin HM, Gohil SK, Harris AD, Keller SC, Klein EY, Krein SL, Kwon JH, Lauring AS, Livorsi DJ, Lofgren ET, Merrill K, Milstone A, Monsees EA, Morgan DJ, Perri LP, Pfeiffer CD, Rock C, Saint S, Sickbert-Bennett E, Skelton F, Suda KJ, Talbot TR, Vaughn VM, Weber DJ, Wiemken TL, Yassin MH, Ziegler MJ, Anderson DJ; SHEA Research Committee.
COVID-19 Research Agenda for Healthcare Epidemiology. *Infect Control Hosp Epidemiol*. 2021 Jan 25:1-81. PMID: 33487199

5. Barlow A, Heil EL, **Claeys KC**.
Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection. *Infect Dis Ther*. 2021 Mar;10(1):605-612. PMID: 33484408
6. Groft LM, **Claeys KC**, Heil EL.
An evaluation of meropenem + vaborbactam for the treatment of nosocomial pneumonia. *Expert Opin Pharmacother*. 2021 Feb;22(3):265-271. PMID: 33090037
7. **Claeys KC**, Zhan M, Pineles L, Lydecker A, Clore G, Goto M, Leekha S, Evans CT, Trautner BW, Goetz MB, Linkin D, Perencevich EN, Morgan DJ.
Conditional reflex to urine culture: Evaluation of a diagnostic stewardship intervention within the Veterans' Affairs and Centers for Disease Control and Prevention Practice-Based Research Network. *Infect Control Hosp Epidemiol*. 2021 Feb;42(2):176-181. PMID: 32838829
8. Bork JT, Leekha S, **Claeys K**, Seung H, Tripoli M, Amoroso A, Heil EL.
Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. *Infect Control Hosp Epidemiol*. 2020 Dec 10:1-3. PMID: 33298211
9. **Claeys KC**, Morgan DJ, Leekha S, Sullivan KV.
Diagnostic and antimicrobial stewardship with molecular respiratory testing across the SHEA Research Network. *Infect Control Hosp Epidemiol*. 2020 Dec 3;1-4. PMID: 33267918
10. **Claeys KC**, Heil EL, Johnson JK, Leekha S.
Management of Gram-Negative Bloodstream Infections in the Era of Rapid Diagnostic Testing: Impact with and Without Antibiotic Stewardship. *Open Forum Infect Dis*. 2020 Sep 12;7(10): ofaa427. PMID: 33134414
11. Vega A, Heil EL, Blackman A, Banoub M, Johnson JK, Leekha S, **Claeys KC**.
Reply to Letters to the Editor: Evaluation of the addition of IV metronidazole to PO vancomycin therapy in critically ill patients with non-fulminant, severe *C. difficile* infection. *Pharmacotherapy*. 2020 Sep;40(9):985-986. PMID: 33112455
12. Vega AD, Jimenez A, Rossello G, **Claeys KC**, Martinez OV, De Pascale B, Perez-Cardona A, Abbo L.
Implementing Carbapenem-resistance Testing Algorithms for *Enterobacteriaceae* and *Pseudomonas*: Diagnostic Antimicrobial Stewardship with timely Infection Prevention. *Diagn Microbiol Infect Dis*. 2020 Aug;97(4):115069. PMID: 32559587
13. Bork JT, **Claeys KC**, Heil EL, Banoub M, Leekha S, Sorkin J, Kleinberg M.
A Propensity Score Matched Study of the Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight. *Antimicrob Agents Chemother*. 2020 Jul 22;64(8): e00307-20. PMID: 32423952
14. Alosaimy S, Molina K, **Claeys KC**, Andrade J, Truong J, King MA, Pullinger BM, Huang G, Morrisette T, Lagnf AM, Rybak MJ.
Early Experience with Eravacycline for Complicated Infections. *Open Forum Infect Dis*. 2020 Mar 2;7(5): ofaa071. PMID: 32411809
15. Vega AD, Blackman AL, Banoub M, Heil EL, Leekha S, Johnson JK, **Claeys KC**.
Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe *Clostridioides difficile* Infection. *Pharmacotherapy*. 2020 May;40(5):398-407. PMID: 32246501

16. **Smith JR**, Rybak JM, **Claeys KC**.
Imipenem-Relebactam: A β -lactamase Inhibitor Awakens. *Pharmacotherapy*. 2020 Apr;40(4):343-356. PMID: 32060929
17. Noval M, Banoub M, **Claeys KC**, **Heil E**.
The Battle Is On: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. *Curr Infect Dis Rep*. 2020 Jan 13;22(1):1. PMID: 31933158
18. Lynch CS, Appleby-Sigler A, Bork JT, Davé R, Agnes K, Sanikop M, Heath D, Clark AF, **Claeys K**, Zhan M, **Morgan DJ**.
Effect of Urine Reflex Culturing on Rates of Cultures and Infections in Acute and Long-Term Care. *Antimicrob Resist Infect Control*. 2020 Jun 29;9(1):96. PMID: 32600416
19. Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, **Claeys KC**, Patel D, **Gopalakrishnan M**.
Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. *Pharmacotherapy*. 2020 Mar;40(3):211-220. PMID: 31957057
20. **Claeys KC**, Heil EL, Brade KD.
Should vancomycin AUC/MIC-based therapeutic drug become standard for patients with confirmed or suspected invasive MRSA infections? Point/Counter Point – Pro. *Can J Hosp Pharm*.
<https://gateway.hshsl.umaryland.edu/eresources.cfm?id=2685>
21. Fornaro R, Heil EL, **Claeys K**, Sheik HF, Zarowitz B, **Brandt NJ**.
Identifying and Bridging the Gaps in Antimicrobial Stewardship in Post-Acute and Long-Term Care. *J Gerontol Nurs*. 2020 Jan 1;46(1):8-13. PMID: 31895956
22. Jorgensen SC, Trinh TD, Zasowski EJ, Langf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, **Claeys KC**, Rosenberg JR, Davis SL, **Rybak MJ**.
Real-world Experience with Ceftazidime-Avibactam for Multi-Drug Resistant Gram-Negative Infections. *Open Forum Infect Dis*. 2019 Dec 6;6(12): ofz522. PMID: 31890725
23. Kena B, Richert ME, **Claeys KC**, Shipper A, Sullivan KV, Schrank GM, O'Hara LM, Morgan DJ, Shanholtz C, **Leekha S**.
Ventilator-Associated Pneumonia: Diagnostic Test Stewardship and Relevance of Culturing Practices. *Curr Infect Dis Rep*. 2019 Nov 21;21(12):50. PMID: 31754887
24. Trinh TD, Jorgensen S, Zasowski EJ, **Claeys KC**, Lagnf AM, Estrada S, Delaportes D, Huang V, Klinker K, Kaye K, Davis SL, **Rybak MJ**.
Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. *Antimicrob Agents Chemother*. 2019 Oct 22;63(11). PMID: 31405859
25. **Claeys KC**, Blanco-Herrera N, Morgan DJ, Leekha SL, **Sullivan KV**.
Advances and Challenges in the Diagnosis and Treatment of Urinary Tract Infections: The Need for Diagnostic Stewardship. *Curr Infect Dis Rep*. 2019 Mar 5;21(4):11. PMID: 30834993
26. **Claeys KC**, Zasowski EJ, Trihn TD, Casapao AM, Pogue JP, Myantt RP, Wilson SS, Welch R, Levine DP, Kaye KS, Delgado G, Murray KP, Davis SL, **Rybak MJ**.
Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant *Staphylococcus aureus*. *Infect Dis Ther*. 2019 Jun;8(2):199-208. PMID: 30915685

27. **Claeys KC**, Hopkins TL, Brown SP, Heil EL.
Perceptions of a transition to an AUC-guided pharmacist-to-dose vancomycin practice at a large academic medical center. *J Am Coll Clin Pharm*. 2019; 2:482–487.
28. Gallagher JC, Molnar E, Satlin M, Elabor A, El-Beyrouy C, Heil E, **Claeys KC**, Dixit D, Hiles J, King M, Vyas N, Harrington N, Guo Y, Saraiya N.
Ceftolozane-tazobactam for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections: A multicenter study. *Open Forum Infect Dis*. 2018 Oct 31;5(11). PMID: 30488041
29. Heil EL, **Claeys KC**, Mynatt RP, Brade K, Hopkins TL, Rybak MJ, Pogue JP.
Making the change to area under the curve–based vancomycin dosing. *Am J Health Syst Pharm*. 2018 Dec 15;75(24):1986-1995. PMID: 30333114
30. **Claeys KC**, Hopkins TL, Vega AD, Heil EL.
Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention. *Curr Infect Dis Rep*. 2018 Mar 23; 20(5):7. PMID: 29572691
31. **Claeys KC**, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ.
Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. *Infect Dis Ther*. 2018 Dec;7(4):495-507. PMID: 30244362
32. Vega AD, Heil EL, **Claeys K**, Hynika L.
Effectiveness of Eight Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HCV/HIV-co-infected Patients. *Antivir Ther*. 2018 Sep 7. PMID: 30192231
33. **Claeys KC**, Schlaffer K, Heil EL, Leekha S, Johnson JK.
Validation of an Antimicrobial Stewardship-Driven Verigene Blood-Culture Gram-Negative Treatment Algorithm to Improve Appropriateness of Antibiotics. *Open Forum Infect Dis*. 2018 Sep 15;5(10): ofy233. PMID: 30568975
34. **Claeys KC**, Pogue JM, Heil EL, Lephart P, Johnson JK.
The Verigene Dilemma: Gram-negative Polymicrobial Bloodstream Infections and Clinical Decision Making. *Diagn Microbiol Infect Dis*. 2018 Jun;91(2):144-146. PMID: 29449043
35. Pogue JM, Mynatt RP, Heil EL, Salimnia H, Johnson JK, **Claeys KC**.
An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: A Tale of Two Cities. *Antimicrob Agents Chemother*. 2018 Apr 26;62(5). PMID: 29483115
36. Masich AM, Heavner MS, Gonzales JP, **Claeys KC**.
Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients. *Curr Infect Dis Rep*. 2018 Apr 4; 20(5):9. PMID: 29619607
37. Heavner MS, Masich AM, **Claeys KC**, Gonzales JP.
Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients. *Curr Infect Dis Rep*. 2018 Apr 5; 20(5):10. PMID: 29623443
38. Trinh TD, Zasowski EJ, **Claeys KC**, Casapao AM, Compton M, Lagnf AM, Kidambi S, Levine DP, Rybak MJ.
Role of vancomycin minimum inhibitory concentrations by modified population analysis profile method in high inoculum methicillin-resistant *Staphylococcus aureus* infections. *Diagn Microbiol Infect Dis*. 2017 Sep;89(1):61-66. PMID: 29470836

39. **Claeys KC**, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, Rybak MJ. Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. *Infect Dis Ther*. 2018 Mar;7(1):135-146. PMID: 29164489
40. Smith JR, Frens J, Smith C, Snider C, **Claeys KC**. Impact of a pharmacist-driven care package on *Staphylococcus aureus* bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study. *Diagn Microbiol Infect Dis*. 2018 Jan;90(1):50-54. PMID: 29153470
41. **Claeys KC**, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ. Novel Application of Published Risk Factors for Methicillin-Resistant *S. aureus* in Acute Bacterial Skin and Skin Structure Infections. *Int J Antimicrob Agents*. 2018 Jan;51(1):43-46. PMID: 28668679
42. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Kidambi S, Davis SL, Rybak MJ. Multidrug-resistant *Pseudomonas aeruginosa* lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. *Diagn Microbiol Infect Dis*. 2017 Sep;89(1):61-66. PMID: 28716451
43. Zasowski EJ, Trinh TD, **Claeys KC**, Casapao AM, Sabagha N, Lagnf AM, Klinker K, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2017 Jan 24;61(2). PMID: 27895012
44. **Claeys KC**, Zasowski EJ, Lagnf AM, Nyguen CT, Nagel JL, Levine DP, Kaye KS, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2016 Sep 23;60(10):5841-8. PMID: 27431221
45. **Claeys KC**, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, Rybak MJ. Pneumonia caused by methicillin-resistant *Staphylococcus aureus*: Does vancomycin heteroresistance matter? *Antimicrob Agents Chemother*. 2016 Jan 4; 60(3):1708-16. PMID: 26729497
46. Zasowski EJ, **Claeys KC**, Lagnf AM, Davis SL, Rybak MJ. Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infection. *Clin Infect Dis*. 2016 May 15;62(10):1242-1250. PMID 26945013
47. **Claeys KC**, Zasowski EJ, Lagnf AM, Rybak MJ. Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection or Illusion? *Am J Infect Control*. 2016 Aug 1;44(8):917-21. PMID: 26388037
48. **Claeys KC**, Lagnf AM, Patel TB, Jacob MG, Davis DL, Rybak MJ. Acute bacterial skin and skin structure infections treated with intravenous antibiotics in the emergency department or observational unit: Experience at the Detroit Medical Center. *Infect Dis Ther*. 2015 Jun;4(2):173-86. PMID: 26055392
49. Casapao AM, Lodise TP, Davis SL, **Claeys KC**, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant *Staphylococcus aureus* infective endocarditis. *Antimicrob Agents Chemother*. 2015 Jun; 59(6): 2978-85. PMID: 25753631

50. **Claeys KC**, Smith JR, Casapao AM, Mynatt RP, Avery L, Schroff A, Yamamura D, Davis SL, **Rybak MJ**. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 2015 Apr; 59(4): 1969-76. PMID: 25605354
51. **Claeys KC**, Fiorvento AD, **Rybak MJ**. A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant *Acinetobacter baumannii*. *Infect Dis Ther*. 2014; 3:69–81. PMID: 25475412
52. Smith JR, **Claeys KC**, Barber KE, Rybak MJ. High dose daptomycin therapy for staphylococcal endocarditis and when to apply it. *Curr Infect Dis Rep*. 2014 Oct; 16(10): 429. PMID: 2516501

Manuscripts in Peer-Reviewed Journals

1. **Claeys KC**, Noval MN. Diagnostic Stewardship to Augment Antimicrobial Stewardship Activities Beyond the Management of Bloodstream Infections. *Contagion Magazine* February 2019
2. **Claeys, KC**. Guidance on How to Measure the Effectiveness of Incorporating Antibigram Data at Your Facility. *AMDA: The Society of Post-Acute and Long-Term Care Medicine* December 2019
3. **Claeys KC**, Morgan DJ, Leekha S. Applying Stewardship Principles to Decrease Unnecessary Urine Culturing. Maryland Department of Health Office of Antibiotic Resistance & Healthcare Associated *Infection Response Newsletter Maryland Department of Health* June 2019
4. **Claeys KC**. Multivariable logistic regression primer for clinicians. *Maryland Health-Systems Pharmacists Pharmascript* April 2018
5. Morrisette T, **Claeys KC**. Five Things to Know About Combination Therapy with Daptomycin Plus Ceftaroline for The Treatment of *Staphylococcus aureus* Bacteremia. *ID Stewardship* www.idstewardship.com March 2018
6. **Claeys KC**. Understanding sensitivity, specificity, positive, and negative predictive value. *Maryland Health-Systems Pharmacists Pharmascript* October 2017
7. Smith JR, **Claeys KC**. Cefiderocol: A 21st Century Trojan Horse. *Society of Infectious Disease Pharmacists Newsletter* October 2017
8. **Claeys KC**. Using the p value to interpret significant results – not the be-all end-all. *Maryland Health-Systems Pharmacists Pharmascript* April 2017
9. Vega AD, Baily J, **Claeys KC**. Advancements in the management of *C. difficile* infections. *MAD-ID Newsletter* April 2017 (ACPE No. 0485-000-17-019-H01-P)
10. **Claeys KC**. MRSA Bloodstream Infection: Daptomycin, Vancomycin Or Other? *ID Stewardship* www.idstewardship.com April 2017
11. Rybak JM, **Claeys KC**. Isavuconazole, a new agent for the treatment of invasive mold infections. *MAD-ID Newsletter* June 2015 (ACPE No. 0485-0000-15-018-H01-P)

12. **Claeys KC**, Dodd P. New and notable medications approved in 2010 and 2011. *Michigan Pharmacist Journal* June 2011 (ACPE No. 112-000-11-009-H01-P)

Textbook Chapters

1. **Claeys KC**, Morgan DJ Coffey KC. (2021) Diagnostic Stewardship. In Bearman G, Munoz-Price S, Morgan DJ, Murthy KR (Eds). *Infection Prevention: New Perspectives and Controversies*, Second Edition. New York, NY, Springer.
2. **Claeys KC**, Blanco N, Leekha S. (2021) The Importance of *C. difficile* Colonization in Infection Prevention. In Bearman G, Munoz-Price S, Morgan DJ, Murthy KR (Eds). *Infection Prevention: New Perspectives and Controversies*, Second Edition. New York, NY, Springer.
3. Smith JR, **Claeys KC**, Zasowski EJ, Yim J, Rybak MJ (2017). Daptomycin Resistance. In Kaye KS, Mayers DL, Sobel JD, et al. (Eds.) *Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1* (pp. 307 - 17). New York, NY, Springer.

Funded Research

1. *Implementation of Clinical Decision Support to Optimize time to Effective Therapy in Multi-Drug Resistant Pseudomonas: Crossroads of Antimicrobial and Diagnostic Stewardship*
Funding: Merck and Co. (\$58, 264.50)
Role: Primary Investigator, 10% effort
11/2020 – present
2. *Diagnostic stewardship as a 'nudge' to reduce inappropriate antibiotic use for urinary tract infections*
Funding: Veterans Affairs HSR & D Scientific Merit Program (\$1,155,942)
Role: Co-investigator, 10% effort
PI: Daniel Morgan, MD, University of Maryland School of Medicine, Baltimore, MD
03/2020 – present
3. *Comparing the clinical utility of rapid diagnostics for the treatment of bloodstream infection using DOOR-MAT*
Funding: GenMark Diagnostics (\$119,600 supplies)
Role: Primary Investigator, 5% effort
11/2018 – 03/2021
4. *Maryland Statewide Prevention and Reduction of C. difficile Collaborative*
Funding: Maryland Department of Health (\$769,743.85)
Role: SPARC Steering Committee & Site Evaluator for Antimicrobial Stewardship, 10% effort
PI: Surbhi Leekha, MBBS, University of Maryland School of Medicine, Baltimore, MD
09/2018 – 12/2020
5. *Comparative Safety and Effectiveness of Isolation in VHA Community Living Centers*
Funding: Veterans Affairs Merit Program (\$292,600.00)
Role: Co-Investigator, 10% effort
PI: Daniel Morgan, MD, University of Maryland School of Medicine, Baltimore, MD
04/2015 – 12/2020

6. *Comparing the clinical utility of rapid diagnostics for the treatment of bloodstream infection* Funding: SIDP (\$10,000) & BioFire Diagnostics LLC (\$163,790 supplies)
Role: Primary Investigator, 5% effort
01/2018 – 01/2020

7. *Improving antibiotic use in long term care patients in Maryland through implementation of core antibiotic stewardship principles*
Funding: Maryland Department of Health and Mental Hygiene (\$200,000)
Role: Educational Committee member and webinar series coordinator, 10% effort
PI: Nicole Brandt, PharmD, University of Maryland School of Pharmacy, Baltimore, MD
01/2018 – 06/2019

8. *Evaluation of reflex urine culture policies to improve antimicrobial use within the VA CREATE Practice Based Research Network (PBRN)*
Funding: Centers for Disease Control and Prevention CREATE PBRN (\$29,212)
Role: Co-Principle investigator with Daniel Morgan, MD, 5% effort
04/2017 – 12/2019

9. *Oral vancomycin plus intravenous metronidazole for severe Clostridium difficile NAP1/BI/027 infection*
Funding: ACCP Resident Research Grants (\$4,564)
Role: Resident Research Project Mentor
PI: Ana D. Vega, PharmD, PGY2 Infectious Diseases, University of Maryland School of Pharmacy, Baltimore, MD (now Jackson Memorial Hospital, Miami, FL)
09/2017 – 03/2019

10. *Design and implementation of a novel interactive application to enhance learning of antimicrobial spectrum of activity*
Funding: University of Maryland School of Pharmacy Disruptive Innovation Competition (\$50,000)
Role: Co-Principle investigator with Emily L. Heil, PharmD & Neha Pandit, PharmD
06/2017 – 06/2019

11. *Improving clinical outcomes in gram-negative bacteremia through a 24-hour multidisciplinary Verigene® gram-negative blood culture treatment pathway*
Funding: Making a Difference in Infectious Diseases (\$27,222.84)
Role: Primary Investigator, 5% effort
06/2017 – 06/2019

12. *Development of dosing model to optimize vancomycin dosing in obese septic patients with MRSA bacteremia*
Funding: ACCP Resident Research Award (\$5,000)
Role: Co-investigator
PI: Jeffrey P. Gonzales, PharmD, FCCM, BCCCP, University of Maryland School of Pharmacy, Baltimore, MD
08/2016 – 08/2018

13. *Use of rapid diagnostics and predictive modeling for MRSA acute bacterial skin and skin structure infections (ABSSSIs) to optimize antibiotic therapy and cost of care in the Emergency Department and Observation Unit*
Funding: Urban Center for Antimicrobial Resistance Discovery Education and Stewardship (UCARDES) Program, Wayne State University (\$50,000)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
11/2015 – 02/2016

14. *Derivation and validation of a risk assessment tool for methicillin-resistant S. aureus acute bacterial skin and skin structure infections (ABSSSIs)*
Funding: Bayer International (\$194,645.75)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
12/2014 – 02/2016
15. *Clinical and economic outcomes of acute bacterial skin and skin structure infections (ABSSSIs): focus on those at risk for methicillin-resistant S. aureus*
Funding: Forest Laboratories/Actavis (\$137,486.90)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
11/2014 – 02/2016
16. *Improving hospital-based antimicrobial prescribing through a multi-system review of antibiotic utilization patterns*
Funding: Michigan Department of Community Health (\$260,263.00)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
01/2014 – 10/2014
17. *Patient outcomes and burden of illness of Gram-negative lower respiratory infections in intensive care units*
Funding: Cubist Pharmaceuticals/Merck (\$151,996.80)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
09/2013 – 06/2016
18. *Impact of early daptomycin versus vancomycin therapy for bloodstream infection caused by methicillin-resistant S. aureus*
Funding: Cubist Pharmaceuticals/Merck (\$177,792.50)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
07/2013 – 11/2015
19. *Prospective evaluation of clinical and economic outcomes of ceftaroline for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) documented or at risk of methicillin-resistant S. aureus*
Funding: Forest Laboratories/Actavis (\$363,815.50)
Role: Co-investigator
PI: Michael J. Rybak, PharmD, PhD, Wayne State University College of Pharmacy, Detroit, MI
07/2013 – 02/2016

Posters & Platforms

1. JT Bork, S Leekha, **KC Claeys**, H Seung, M Tripoli, A Amoroso, E Heil. *Change in Hospital Antibiotic Use and Acquisition of Multidrug Resistant Gram-Negative Organisms After Onset of Coronavirus Disease 2019*. ESCMID Conference on Coronavirus Disease [Virtual Conference], September 2020 [poster]

2. Noval M, Bhatt M, Colletto A, Armahizer M, Leekha S, **Claeys KC**. *Evaluating the incidence of bacteriuria in female patients before and after implementation of external catheter devices*. IDWeek [Virtual Conference], October 2020 [poster]
3. Noval M, Heil EL, Willaims P, Johnson JK, **Claeys KC**. *Comparison of cefazolin susceptibilities of Enterobacterales with an automated susceptibility testing platform versus in vitro antimicrobial testing*. IDWeek [Virtual Conference], October 2020 [poster]
4. **Claeys KC**, Smith RD, Leekha S, Johnson JK. *Comparison of Molecular Rapid Diagnostic Testing Panels for Gram-negative Bacteremia using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT)*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
5. **Claeys KC**, Heil EL, Johnson JK, Leekha L. *Comparing Clinical Outcomes in Gram-negative Bloodstream Infections with Desirability of Outcomes Ranking: Focus on Non-Fermenting Organisms*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
6. Bork J, **Claeys KC**, Heil EL, Banoub M, Leekha S, Sorkin J, Kleinberg M. *The Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight: A propensity-score matched study*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [oral platform]
7. Alosaimy S, Molina K, **Claeys KC**, Andrade J, Troung J, King M, Pullinger B, Haung G, Morrisette T, Lagnf AM, Rybak MJ. *Real-World Multicenter Experience with Eravacycline at Academic Hospital Systems*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
8. Alosaimy S, Lagnf AM, Jorgensen S, Morrisette T, Carlson T, Jo J, Garey K, Allen D, Venugopalan V, Davis SL, Veve M, Claeys KC, Athans V, Saw S, Ortwine J, Yost, Mynatt R, Pogue J, Rybak MJ. *Real-World Multicenter Experience of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
9. Smith RD, Hitchcock S, Johnson JK, **Claeys KC**. *Comparison of Three Rapid Diagnostic Blood Culture Identification Panels for Gram-Negative Bloodstream Infections*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
10. McCrink KA, DeRonde KJ, Jimenez A, Rosello G, Natori Y, **Claeys KC**, Martinez OV, DePascale B, Perez-Cardona A, Abbo L, Vega AD. *Impact of Diagnostic and Antimicrobial Stewardship on Time-to-Appropriate Therapy and Clinical Outcomes in Infections caused by Carbapenem-resistant Gram-negative Organisms*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [mini oral session]
11. Rock C, Perlmutter RF, Blythe D, Bork J, **Claeys KC**, Cosgrove SE, Dzintars K, Fabre V, Harris AD, Heil EL, Hsu YJ, Keller S, Maragakis LL, Milstrone AM, Morgan DJ, Brooks R, Leekha S. *SPARC (Statewide Prevention and Reduction of Clostridiodes difficile) collaborative; a unique Maryland public health-academic medicine partnership reduced CDI across the state*. Society of Healthcare Epidemiology or America Decennial Meeting 2019, Atlanta, GA [Poster]
12. Howard AK, **Claeys KC**, Parbuoni K, Biggs J, Johnson JK, Luneburg P, Campbell J, Morgan JA. *Comparative effectiveness of pediatric and neonatal antimicrobial stewardship treatment algorithms in rapid diagnostic-detected bacteremia*. ACCP Global Conference on Clinical Pharmacy, October 2019, New York, NYC [Poster]

13. Blackman AL, Ali S, Gao X, Mesumbe R, Cheung C, Banoub M, **Claeys KC**, Heil EL. *Evaluation of intraoperative topical vancomycin and the incidence of acute kidney injury*. IDWeek, October 2019, Washington, DC[Poster]
14. Vega AD, Blackman AL, Banoub M, Heil EL, Leekha S, Johnson JK, **Claeys KC**. *No Mortality Benefit to Adding Intravenous Metronidazole to Oral Vancomycin for Critically ill Patients with Severe C. difficile Infection*. IDWeek, October 2019, Washington, DC[Poster]
15. **Claeys KC**, Heil EL, Loughry N, Chainani S, Johnson JK, Leekha S. *Use of Rapid Diagnostic Testing in Gram-negative Bloodstream Infections with and without Antimicrobial Stewardship*. IDWeek, October 2019, Washington, DC[Poster]
16. **Claeys KC**, Schlaffer KS, Kpadeh-Rogers Z, Evans SR, Jiang Y, Johnson JK, Leekha S. *Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-negative Bloodstream Infection using a Desirability of Outcomes Ranking*. IDWeek, October 2019, Washington, DC[Poster]
17. **Claeys KC**, Hopkins TL, Kpadeh-Rogers Z, Evans SR, Jiang Y, Johnson JK, Leekha S. *Comparison of Rapid Diagnostic Tests for Bloodstream Infections using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT)*. IDWeek, October 2019, Washington, DC[Poster]
18. Lynch CS, **Claeys KC**, Appleby-Sigler A, Bork JT, Davé R, Agnes J, Clark AD, Morgan DJ. *Effect of Reflex Urine Culturing on Rates of Cultures and Infections in an Acute Care Hospital, Emergency Department, and Two Long-Term Care Facilities*. IDWeek, October 2019, Washington, DC[Poster]
19. Johnson JK, Kpadeh-Rogers Z, Paszkiewicz G, **Claeys KC**. *Comparison of the Verigene® and the ePlex® Blood Culture Identification Panels for Gram-Positive and Gram-Negative Bloodstream Infections*. IDWeek, October 2019, Washington, DC[Poster]
20. Bork JT, **Claeys KC**, Johnson JK, Obiekwe U, Lusby M, Jones J, Heil EL, Leekha S. *Back to the Future: The Impact of Multi-step Algorithm C. difficile Testing at a Large Tertiary Medical Center*. IDWeek, October 2019, Washington, DC[Poster]
21. Ali S, **Claeys KC**. *Derivation of a Prediction Model for Risk of Drug-Resistant Urinary Tract Infection*. IDWeek, October 2019, Washington, DC[Poster]
22. Masich A, Kalaria S, Gonzales J, Heil E, Tata A, **Claeys KC**, Patel D, Gopalakrishnan M. *Comparison of Vancomycin Trough Attainment in Obese Septic Patients Versus Non-Obese Septic Patients*. Society of Critical Care Medicine (SCCM), February 2019, San Diego, CA [Platform]
23. Masich A, Kalaria S, Gonzales J, Heil E, Tata A, **Claeys KC**, Patel D, Gopalakrishnan M. *Characterization of vancomycin pharmacokinetics and pharmacodynamics in obese septic shock patients*. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
24. **Claeys KC**, Hopkins TL, Heil EL. *Perceptions of a transition to an AUC-guided pharmacist-to-dose vancomycin practice at a large academic medical center*. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
25. **Claeys KC**, Callahan P, Vega AD, Heil EL. *Impact of an AUC-guided versus trough-guided vancomycin dosing strategy*. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]

26. Vega AD, Nguyen C, **Claeys KC**, Heil EL. *Characterizing variability in calculated vancomycin pharmacokinetic parameters using an AUC-based dosing strategy in hospitalized patients*. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
27. Zasowski EJ, Trinh TD, **Claeys KC**, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Pulido Cejudo A, Henrique Melo L Cao B, Rybak MJ. *International validation of a Methicillin-Resistant Staphylococcus aureus (MRSA) risk assessment tool for acute bacterial skin and skin structure infections (ABSSSI)*. IDWeek, October 2018, San Francisco, CA [Poster]
28. Vega AD, Hopkins TL, Heil EL, Johnson JK, Leekha S, **Claeys KC**. *Oral vancomycin plus intravenous metronidazole for severe Clostridium difficile infection in critically ill patients*. IDWeek, October 2018, San Francisco, CA [Poster]
29. **Claeys KC**, Loughry N, Chainani S, Leekha S, Heil EL. *Oral antibiotics for the treatment of Gram-negative bloodstream infections: Prescribing practices and outcomes at a large academic medical center*. IDWeek, October 2018, San Francisco, CA [Poster]
30. Johnson N, Mattingly TJ, Johnson JK, **Claeys, KC**. *Review of VERIGENE blood culture errors and discrepancies reported at a large academic medical centre*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
31. Nguyen C, Heil EL, **Claeys KC**. *Can previously published literature combined with a small institution-specific data-set aid in the prediction of drug resistance in pneumonia presenting from the community?* European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
32. Johnson JK, **Claeys KC**, Heavner M, Jani N, Leekha S. *The first KPC-producing Acinetobacter baumannii complex in continental USA*. Infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
33. AM Lagnf, SC Jorgensen, EJ Zasowski, TD Trinh, **KC Claeys**, KP Klinker, SJ Estrada, SL Davis, V Huang, BA Potoski, DP Levine, KS Kaye, MJ Rybak. *A retrospective analysis of clinical outcomes in patients treated with vancomycin or daptomycin or ceftaroline for Methicillin-Resistant Staphylococcus aureus bloodstream infections*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
34. Molnar EM, Heil EL, **Claeys KC**, Hiles J, Gallagher JC. *Ceftolozane-tazobactam for the treatment of multi drug resistant Pseudomonas aeruginosa (MDRPA) infections: A multicenter study*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
35. Hanretty A, Bia T, **Claeys KC**, King M, Peahota M, Gallagher JC. *Comparison of acute kidney injury of beta-lactam/beta-lactamase inhibitor combinations compared to polymyxins in the treatment of multidrug-resistant Gram-negative infections*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
36. Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, **Claeys KC**, Patel D, Gopalakrishman M. *Characterization of vancomycin pharmacokinetics and pharmacodynamics in obese septic patients with Gram-Positive bacteremia*. ACCP Global Conference on Clinical Pharmacy, October 2017, Tucson, AZ [Poster]
37. **Claeys, KC**, Pogue JP, Lephart P, Heil EL, Johnson JK. *Gram-Negative polymicrobial bloodstream infections and clinical decision making with a microarray testing system*. IDWeek, October 2017, San Diego, CA [Poster]

38. Schlaffer K, Heil EL, Leekha S, Johnson JK, **Claeys KC**. *Validation of an antimicrobial stewardship driven Verigene® blood-culture gram-negative treatment algorithm to improve appropriateness of antibiotics*. IDWeek, October 2017, San Diego, CA [Poster]
39. Heil EL, Sivasailam B, Park S, Diaz J, von Rosenvinge E, **Claeys KC**, Hopkins TL, Leekha S. *Impact of a multi-disciplinary C. difficile action team*. IDWeek, October 2017, San Diego, CA [Poster]
40. Vega AD, Hynick L, **Claeys KC**, Heil EL. *Effectiveness of 8- or 12-week treatment duration of Ledipasvir/Sofosbuvir for Hepatitis C: Evidence from a large academic medical center*. IDWeek, October 2017, San Diego, CA [Poster]
41. Molnar EM, Heil EL, **Claeys KC**, Hiles J, Gallagher JC. *Ceftolozane-tazobactam for the Treatment of Multi Drug Resistant Pseudomonas aeruginosa (MDRPA) Infections*. IDWeek, October 2017, San Diego, CA [Poster]
42. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Delaportas D, Estrada SJ, Davis SL, Klinker KP, Huang V, Potoski BA, Levine DP, Kaye KS, Bonine NG, Gillard P, Rybak MJ. *Clinical and economic comparison of Ceftaroline Fosamil (CPT) and Daptomycin (DAP) for Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)*. IDWeek, October 2017, San Diego, CA [Poster]
43. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Delaportas D, Estrada SJ, Davis SL, Klinker KP, Huang V, Kaye KS, Bonine NG, Gillard P, Rybak MJ. *Ceftaroline Fosamil (CPT) versus vancomycin (VAN) for acute bacterial skin and skin structure infections (ABSSSI)*. IDWeek, October 2017, San Diego, CA [Poster]
44. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Sabagha N, Sherwin RL, Welch RD, Rybak MJ. *Clinical characteristics of patients with skin and soft tissue infections (SSTI) presenting to the emergency department: A focus on Methicillin-Resistant Staphylococcus aureus (MRSA) risk and antibiotic prescribing*. ASM Microbe, June 2017, New Orleans, LA [Poster]
45. **Claeys KC**, Heil EL, Johnson JK, Lephart P, Mynatt RP, Salimnia H, Pogue JM. *An antibiotic stewardship programme (ASP) blueprint for optimizing Verigene BC-GN within an institution: a tale of two cities*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2017, Vienna, Austria [Poster]
46. Trinh TD, Zasowski EJ, **Claeys KC**, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Cejudo A, Melo L, Cao B, Rybak MJ. *International validation of a risk-assessment tool for Methicillin-Resistant Staphylococcus aureus acute bacterial skin and skin-structure infections*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2017, Vienna, Austria [Poster]
47. Smith JR, Frens J, Smith C, Snider C, **Claeys KC**. *Effects of a Staphylococcus aureus bacteremia care package intervention on patient care in a community teaching hospital: A propensity-score matched comparison*. IDWeek, October 2016, New Orleans, LA [Poster]
48. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. *Use of Intravenous versus oral antibiotics in the emergency department/observation unit (ED/OU) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs)*. ASM Microbe, June 2016, Boston, MA [Poster]
49. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Davis SL, Rybak MJ. *Predictors of multidrug resistant (MDR) Pseudomonas aeruginosa nosocomial pneumonia in the intensive care unit (ICU)*. ASM Microbe, June 2016, Boston, MA [Poster]

50. **Claeys KC**, Levine DP. *Length of bacteraemia and mortality in S. aureus infective endocarditis*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [E-Poster]
51. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. *Relationship between duration of methicillin-resistant Staphylococcus aureus bloodstream infection and mortality*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [Poster]
52. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. *Ceftaroline Fosamil for the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [E-Poster]
53. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. *Burden of illness with Gram-negative (GN) lower respiratory infections (LRTIs) admitted to intensive care units (ICUs)*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
54. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. *Risk Assessment and severity analysis in acute bacterial skin and skin structure infections (ABSSSIs)*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
55. Zasowski EJ, **Claeys KC**, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. *Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant Staphylococcus aureus pneumonia*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
56. Zasowski EJ, **Claeys KC**, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. *Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
57. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. *Practical application of risk factors for methicillin-resistant Staphylococcus aureus (MRSA) in the treatment of antibacterial skin and skin structure infections (ABSSSI)*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
58. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, DP Levine, KS Kaye, Rybak MJ. *Propensity Matched analysis of daptomycin versus vancomycin for bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA)*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
59. Zasowski EJ, **Claeys KC**, Lagnf AM, Witt JS, Rybak MJ. *Predictors of vancomycin-resistant enterococci among patients with community-onset enterococcal bloodstream infections*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
60. Zasowski EJ, **Claeys KC**, Lagnf AM, Witt JS, Rybak MJ. *Linezolid versus high-dose daptomycin for the treatment of vancomycin-resistant enterococcus bloodstream infections*. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]

61. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. *Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department (ED) or observation unit (OU): Experience at the Detroit Medical Center.* Making a Difference in Infectious Disease (MAD-ID), May 2015, Orlando, FL [Poster]
62. **Claeys KC**, Lagnf AM, Gravelin A, Hallesy J, Alderson R, Davis SL, Rybak MJ. *Clinical outcomes of patients with heterogeneous vancomycin-intermediate S. aureus (hVISA) lower respiratory tract infections.* European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2015, Copenhagen, Denmark [Poster]
63. **Claeys KC**, Lagnf AM, Rybak MJ. *Length of enterococcal bacteremia and associated clinical outcomes.* European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2015, Copenhagen, Denmark [Poster]
64. **Claeys KC**, Casapao AM, Davis DL, Rybak MJ. *Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department or observational unit: Experience at the Detroit Medical Center.* Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
65. **Claeys KC**, Nagel JL, Pogue JM, Casapao AM, Finks K, Neuhauser M, Schneider A, Davis SL, and Rybak MJ. *Implementing the National Healthcare Safety Network's (NHSN's) Antimicrobial Use Option to aid in determination of resistance among key nosocomial pathogens.* Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
66. Nagel JL, Pogue JM, **Claeys KC**, Casapao AM, Finks J, Rybak MJ. *Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module (CDC AUR) to compare multicenter antimicrobial use.* Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
67. **Claeys KC**, Casapao AM, Pogue J, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine D, Kaye K, Delgado G, Giuliano CA, Talka R, Johnson LB, Davis SL, Rybak MJ. *Rapid diagnostic testing with GeneXpert improves enrollment in a randomized clinical trial for detection of methicillin-resistant S. aureus in acute bacterial skin and skin structure infections.* European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2014, Barcelona, Spain [Poster]

Professional Presentations

National & International

1. *Comparing the Utility of Rapid Diagnostics for the Treatment of Bloodstream Infections using DOOR-MAT.* Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting, November 2020 online
2. *Breakpoints Podcast: Expert updates on gram-negative resistance Q & A session.* Society of Infectious Diseases Pharmacists (SIDP) Education Center Podcast, July 2020 online
3. *Expert updates in gram-negative resistance.* Society of Infectious Diseases Pharmacists (SIDP) Education Center Online Webinar, June 2020
4. In-depth Symposium: Use of molecular rapid diagnostics in gram-negative bloodstream Infections. ASM Microbe 2020 – cancelled due to COVID-19

5. *Combining Laboratory and Antimicrobial Stewardship to Create a Better Patient Care Pathway for Diagnosis of Bloodstream Infections.*
IDWeek Learning Lounge, October 2019, Washington, DC
6. *Optimizing Rapid Diagnostic Tests for the Management of Bloodstream Infections.*
Maryland Statewide Prevention and Reduction of *C. difficile* Collaborative (SPARC) webinar series, July 2019
Baltimore, MD.
7. *The Basic of Infectious Diseases Management in Hospice and Palliative Care.*
Hospice & Palliative Care Medical Director's Symposium, May 2019, Columbia, Maryland
8. *Changes in Clostridioides difficile (Clostridium difficile) Laboratory Testing.*
Infectious Diseases Grand Rounds, University of Maryland Medical Center, February 2019, Baltimore, MD.
9. *How to Measure the Effectiveness of Incorporating Antibigram Data at Your Facility.*
Peter Lamy Center on Drug Therapy and Aging Webinar, February 2019, Baltimore, MD. ACPE: 0025-0000-19-010-L01-P
10. *Use of Rapid Diagnostic Test in Bloodstream Infections to Improve Patient Outcomes and Antimicrobial Stewardship Initiatives.* January 2019, Baltimore, MD. ACPE: 0025-9999-19-007-L01-P
11. *Applying Appropriate Biostatistics for Clinical Research.* University of Maryland Medical Center Preceptor Development Series, November 2018, Baltimore, MD
12. *Clinical and Economic Benefits of Sustaining and Expanding Stewardship Programs.*
American College of Clinical Pharmacy, 2018 Global Conference, October 2018, Seattle, WA. ACPE: 0217-0000-18-201-L01-P
13. *Clinical Insights: Strategic Implementation of a Rapid Molecular Blood Culture Panel for Gram-Negative Bacteremia.* Luminex Corp., October 2018, XTalks Online Webinar
14. *Microbiology, Antibigrams, and Anti-Infective Basics 101.*
Maryland Long Term Care Antimicrobial Stewardship Summit, September 2018, Columbia, MD. ACPE No. 0025-0000-18-112-L04-P
15. *Improving Clinical Outcomes in Gram- Negative Bacteremia through a Multidisciplinary Rapid Diagnostic Treatment Pathway.*
University of Maryland School of Pharmacy Research Seminar Series, September 2017, Baltimore, MD. ACPE No. 0025-0000-17-019-L01-P
16. *Improving Clinical Outcomes in Gram- Negative Bacteremia through a Multidisciplinary Rapid Diagnostic Treatment Pathway.*
Maryland CAAUSE Antibiotic Stewardship Meeting, March 2018, Baltimore, MD
17. *Back to Basics – Dosing of Aminoglycosides.*
Maryland Society of Health-Systems Pharmacists Infectious Disease CE Dinner, September 2016, Baltimore, MD. ACPE No. 0025-9999-16-096-L01-P
18. *Skin and Skin Structure Infections: Risk assessment and decision analysis to improve clinical outcomes.*
Annual Infectious Diseases Fellowship Forum, May 2015, Brainerd, MN

19. *Developing a risk assessment tool for MRSA ABSSSI.*
Bayer International Global Council Meeting, April 2015, Copenhagen, Denmark
20. *Impact of early daptomycin versus vancomycin in methicillin-resistant Staphylococcus aureus bacteremia.*
Annual Infectious Diseases Fellowship Forum, April 2014, Captiva Island, FL

Media Contributions

1. *Most institutions use rapid viral tests, but stewardship practices are uncommon.* [Infectious Diseases News](#). December 2020
2. *Rapid diagnostics for gram-negative bloodstream infections.* [Pharmacy Times Contagion Live](#). June 2019
3. *Why ID? Experts Share The 'Why' That Drove Them to Pursue Infectious Disease Careers.* [Pharmacy Times Contagion Live](#). May 2019
4. *Evaluating rapid diagnostics for bloodstream infections without stewardship involvement.* [Pharmacy Times Contagion Live](#). May 2019
5. *Treatment algorithm an asset for antibiotic stewardship.* [Infectious Diseases News](#). October 2018
6. *Novel cephalosporin agent with broad gram-negative activity shows promise in clinical trial for complicated urinary tract infections.* [Pharmacy Times Contagion Live](#). December 2017
7. *Reality versus expectation: Being an Infectious Diseases Pharmacy Fellow.* [ID Stewardship](#). August 2016

Awards & Recognition

Society of Healthcare Epidemiology of America Top Poster Abstract Award	03/2020
American College of Clinical Pharmacy Pharmacotherapy Reviewer of the Year	10/2019
European Congress of Clinical Microbiology and Infectious Diseases Travel Grant	01/2018
Making a Difference in Infectious Disease (MAD-ID) Travel Grant	04/2015
Interscience Conference on Antimicrobial Agents and Chemotherapy Infectious Disease Fellows Grant Program	06/2014
European Congress of Clinical Microbiology and Infectious Diseases Travel Grant	02/2014
University of Illinois at Chicago College of Pharmacy Richard A. Hutchinson Award for Excellence in Pharmacy Practice	06/2013
Eugene Applebaum College of Pharmacy and Health Sciences Honors Convocation: Award for Outstanding Professional and Community Service	05/2012

Southeastern Michigan Society of Health-System Pharmacists Student Research Award	11/2011
Michigan Pharmacists Association Good Government Award	02/2011
Eugene Applebaum College of Pharmacy and Health Sciences John Helfman Pharmacy Merit Scholarship	05/2011

Professional Membership

National Associations

The Society for Healthcare Epidemiology of America	2017 – present
Infectious Diseases Society of America	2014 – 2016
European Society of Clinical Microbiology and Infectious Diseases	2013 – present
Society of Infectious Diseases Pharmacists	2013 – present
American College of Clinical Pharmacy	2011 – present

State & Local Associations

Maryland Society of Health-System Pharmacists	2016 – present
Phi Lambda Sigma Leadership Society, Gamma Chi Chapter	2010 – 2012
Rho Chi Academic Honors Society, Alpha Chi Chapter	2010 – 2012